Quality of Life Research

, Volume 6, Issue 6, pp 531–554 | Cite as

Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS

  • A. W. Wu
  • R. D. Hays
  • S. Kelly
  • F. Malitz
  • S. A. Bozzette


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tarlov AR, Ware JE, Greenfield S, Nelson E, Perrin E, Zubkoff M. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA, 1989; 262: 925–930.Google Scholar
  2. 2.
    Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724–735.Google Scholar
  3. 3.
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.Google Scholar
  4. 4.
    Stewart A L, Sherbourne CD, Hays RD et al. Summary and discussion of MOS measures. In: Stewart AL, Ware JE. eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham: Duke University Press, 1992: 345–371.Google Scholar
  5. 5.
    Hays RD, Sherbourne CD, Mazel RM. User's Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. Santa Monica, CA: RAND, 1995.Google Scholar
  6. 6.
    Ware JE, Sherbourne CD, Davies AR. Developing and testing the MOS 20-item short-form health survey: a general population application. In: Stewart AL, Ware JE, eds., Measuring functioning and well-being: The Medical Outcomes Study Approach. Durham: Duke University Press, 1992: 277–290.Google Scholar
  7. 7.
    Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992; 116: 129–137.Google Scholar
  8. 8.
    Holmes W, Bix B, Shea J. SF-20 score and item distributions in a human immunodeficiency virus-seropositive sample. Med Care 1996; 34: 562–569)Google Scholar
  9. 9.
    Smith MY, Feldman J, Kelly P, DeHovitz JA, Chirgwin K, Minkoff H. Health-related quality of life of HIV-infected women: evidence for the reliability and responsiveness of the Medical Outcomes Study Short-Form 20. Qual Life Res 1996: 5: 47–55.Google Scholar
  10. 10.
    Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29: 786–798.Google Scholar
  11. 11.
    Burgess A, Dayer M, Catalan J, Hawkins K, Gazzard B. The reliability and validity of two HIV-specific health related quality of life measures: a preliminary analysis. AIDS 1993; 7: 1001–1008.Google Scholar
  12. 12.
    Wu AW, Lichter SL, Richardson W et al. Quality of life in patients receiving clarithromycin for Mycobacterium avium complex infection and AIDS. In: Eighth International Conference on AIDS/III STD World Congress, Amsterdam, 19–24 July 1992.Google Scholar
  13. 13.
    Scott-Lennox J, McLaughlin Miley CJ, Mauskopf JA. Impact of lamivudine and zidovudine therapy on quality of life (QOL). In: XI International Conference on AIDS, Vancouver, 7–12 July 1996.Google Scholar
  14. 14.
    Wu AW, Jacobson D, Grant D, Scott-Lennox J. Quality of life scores predict clinical trial attrition and mortality. Abstracts 4th Conf Retroviruses Opportun Infect. 1997; 31: 298.Google Scholar
  15. 15.
    Revicki DA, Wu AW, Brown R. Change in clinical status, health status and health utility outcomes in HIV-infected patients. Med Care 1995; 33: AS173–AS182.Google Scholar
  16. 16.
    Revicki DA, Swartz C. Quality of life outcomes of saquinavir, zalcitabine, and combination saquinavirzalcitabine therapy for advanced HIV-infection. Abstracts 4th Conf Retroviruses Opportun Infect. 1997; 27: 266.Google Scholar
  17. 17.
    Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical trial and nonclinical trials human immunodeficiency virus-infected cohorts. Med Care 1995; 33: AS15–25.Google Scholar
  18. 18.
    Bozzette SA, Hays RD, Berry SH, Kanouse DE. A perceived health index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994; 32: 716–31.Google Scholar
  19. 19.
    Bozzette SA, Hays RD, Berry S, Kanouse DE, Wu A. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J AIDS. 1995; 8: 253–65.Google Scholar
  20. 20.
    Bozzette SA, Finkelstein DM, Spector et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693–69.Google Scholar
  21. 21.
    Bozzette SA, Kanouse DE, Berry S, Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS: a randomized controlled trial (ACTG 114). JAMA. 1995; 273: 295–301.Google Scholar
  22. 22.
    Bozzette SA, Kanouse DE, Duan N, Berry S, Richman D for the ACTG 116/117 Study Group. The impact of zidovudine compared to didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. Antiviral Chemother 1996; 1: 21–32.Google Scholar
  23. 23.
    Bozzette SA, Berry SH, Duan N, Kanouse D. Measuring Patient-Centered Outcomes in ACTG 116/117: Instruments, Methods, Application, and Results. RAND, 1996Google Scholar
  24. 24.
    Spector SA, McKinley GF, Lalezari JP et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med, 1996; 334: 1491–7.Google Scholar
  25. 25.
    Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaulation of chemotherapeutic agents. New York; Columbia University Press, 1947.Google Scholar
  26. 26.
    Holmes WC, Bix B, Meritz M, Turner J, Hutelmyer C. Human immunodeficiency virus (HIV) infection and quality of life: the potential impact of axis I psychiatric disorders in a sample of 95 HIV seropositive men. Psychosom Med 1997; 59: 187–192.Google Scholar
  27. 27.
    Davidson A, Rietmeijer C, Hagglund B, Paulson A, St John M, Cohn D. Relation of social factors to health care utilization and health status assessment in HIV-infected patients. In: Eighth International Conference on AIDS, Amsterdam, July 1992.Google Scholar
  28. 28.
    Bertram S, Reitmeijer C, Hagglund, Cohn K, St John M, Davidson A: health status measures (HSM) in HIV infected women and men. In: Ninth International Conference on AIDS, Berlin, June 1993.Google Scholar
  29. 29.
    Fleishman J, Hsia DC, Hellinger FJ. Correlates of medical service utilization among people with HIV infection. Health Service Res 1994; 29: 527–48.Google Scholar
  30. 30.
    Bindman AB, Keane D, Lurie N. Measuring health changes among severely ill patients. The floor phenomenon. Med Care 1990: 28: 1142–1152.Google Scholar
  31. 31.
    Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res, 1997; 6: 479–491.Google Scholar
  32. 32.
    Wu AW, Jacobson D, Berzon R et al. The effect of mode of administration on Medical Outcomes Study health ratings and EuroQol scores in AIDS. Qual Life Res, 1997; 6: 1.Google Scholar
  33. 33.
    Zander KJ, Palitzsch M, Kirchberger I et al. HIV-infektion und gesundheitsbezogene Lebensqualität: psychometrische prüfung der deutschsprachigen version de “MOS-HIV”-fragebogens zur therapieerfolgskontrolle. (HIV infection and health related quality of life: psychometric testing of the German version of the MOS-HIV questionnaire.) AIDS-Forschung (AIFO) 1994; 9: 241–249.Google Scholar
  34. 34.
    Rissi M, Marchesi S, Morelli E, Avogardi M. Quality of life in PWAs, Evaluation by the Medical Outcomes Instrument. AIDS Patient Care 1994; 10: 265–268.Google Scholar
  35. 35.
    Scott-Lennox JA, Boyer JG, Ware JE, Wu AW. A psychometric validation of French, German, Italian, Dutch, and UK English translations of the MOS-HIV health status questionnaire. In press.Google Scholar
  36. 36.
    Wu AW, Jacobson D, Clark B, Berzon R, Scott-Lennox J. Reliability, validity and responsiveness of the MOS-HIV HRQL instrument after cultural adaptation in Europe: Results from an international clinical trial. In: Third Annual DIA Symposium on Quality of Life Evaluation, Boston, 9–10 May 1996.Google Scholar
  37. 37.
    Wu AW, Jacobson D, Clark B, Brookmyer R, Feinberg J. Quality of life associated with valacyclovir vs. high and low dose acyclovir for prophylaxis against cytomegalovirus in AIDS. Abstracts 4th Conf Retroviruses Opportun Infect. 1997; 31: 297.Google Scholar
  38. 38.
    Carretero MD, Burgess AP, Soler P, Soler M, Catalan J. Reliability and validity of an HIV-specific health related quality of life (QoL) measure for use with injecting drug users. AIDS 1996; 10: 1699–1705.Google Scholar
  39. 39.
    Copfer AE, Ampel NM, Hughes TE et al. The use of two measures of health-related quality of life in HIV-infected individuals: a cross-sectional comparison. Qual Life Res 1996; 5: 281–286.Google Scholar
  40. 40.
    Ganz PA, Schag CAC, Kahn B, Petersen L. Assessing the quality of life of HIV infected persons: clinical and descriptive information from studies with the HOPES. Psychol Health 1994; 9: 93–110.Google Scholar
  41. 41.
    Doob PR, Johnson KM, St Cyr J, MacFadden DK. Soft and hard measures of energy/fatigue in HIV Trials. In: XI International Conference on AIDS, Vancouver 7–12 July 1996.Google Scholar
  42. 42.
    Zander K, Jager H, Palitzsch M, Poppinger JV Steinbuchel N, Bullinger M. Health related quality of life (HRQL) in HIV disease: influence of symptom load, functioning, mood and coping styles. In: Ninth International Conference on AIDS, Berlin, June 1993.Google Scholar
  43. 43.
    Schag CA, Ganz PA, Kahn B, Petersen L. Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES). Qual Life Res 1992; 1: 397–413.Google Scholar
  44. 44.
    Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the MOS HIV health survey. Med Care in press.Google Scholar
  45. 45.
    The SOCA Research Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol, 1996; 114.Google Scholar
  46. 46.
    Wu AW, Coleson L, Holbrook J, Jabs DA. Measuring visual function and quality of life in CMV retinitis: development and preliminary validation of an instrument. Arch Ophthalmol 1996; 114: 841–847.Google Scholar
  47. 47.
    Safrin, S, Finkelstein, DM, Feinberg, J et al. Comparison of three regimens for treatment of mild to moderate pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med, 1996; 124: 792–802.Google Scholar
  48. 48.
    Wu AW, Gray S, Brookmeyer R, Safrin S. Quality of life in a double-blind randomized trial of 3 oral regimens for mild-to-moderate pneumocystis carinii pneumonia in AIDS (ACTG 108). In XI International Conference on AIDS. 7–12 July 1996. Vancouver.Google Scholar
  49. 49.
    Givertz F, Revicki DA. Discriminant validity of the medical outcomes study cognitive function scale in HIV disease patients. In: International Society of Quality of Life Research, Montreal, Quebec, 14–17 October 1995.Google Scholar
  50. 50.
    Chaisson RE, Benson CA, Dube MP and the AIDS Clinical Trails Group Protocol 157 Study Team. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–911.Google Scholar
  51. 51.
    Jacobson JM, Greenspan JS, Spritzler J et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1487–1493.Google Scholar
  52. 52.
    Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 865–872.Google Scholar
  53. 53.
    Hooker M, Newberry A, Nunn A et al. Changes in quality of life (QOL) indices by treatment group for Delta trial participants beginning HIV therapy. In: XI International Conference on AIDS, Vancouver, 7–12 July 1996. Google Scholar
  54. 54.
    Wu AW, Rubin HR, Mathews WC, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early AIDS-related complex. J AIDS 1993; 6: 452–458.Google Scholar
  55. 55.
    Ware JE, Kosinski M, Bayliss MS et al. Comparison of methods for the scoring and statistical analysis of the SF-36 health profile and summary measures: results from the Medical Outcomes Study. Med Care 1995; 33: A5264–A5279.Google Scholar
  56. 56.
    Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.Google Scholar
  57. 57.
    Ware JE, Keller SD, Gandek B, Brazier J, Sullivan M and the IQOLA Project Group. Evaluating translations of health status questionnaires: methods from the IQOLA Project. Int J Technology Assessment in Health Care, 1995; 11: 525–551.Google Scholar
  58. 58.
    Lamping DL. Measuring quality of life in HIV infection: validation of the SF-36 Short-Form Health Survey. In: IXth International Conference on AIDS. Berlin, June 1993.Google Scholar
  59. 59.
    Tsevat J, Solzan JG Kuntz KM et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care, 1996; 34: 44–57.Google Scholar
  60. 60.
    O'Keefe EA, Wood R. The impact of human immunodeficiency virus (HIV) infection on quality of life in a multiracial South African population. Qual Life Res 1996; 5: 275–80.Google Scholar
  61. 61.
    Devlin R, Messina M, Dunkle A, Cross A, Sudlovsky A. Comparative assessment of baseline quality of life in a double-blind randomized trial of d4T vs ZDV using 3 different instruments. In: 33rd ICAAC. New Orleans: October 1993.Google Scholar
  62. 62.
    Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Service Res 1976; 11: 478.Google Scholar
  63. 63.
    Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: Contents, interobserver agreements, and physiologic correlates of two new clinical indexes. Chest 1984; 51: 730.Google Scholar
  64. 64.
    Radloff LS. The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385–401.Google Scholar
  65. 65.
    Viet CT, Ware JE Jr. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983; 51: 730.Google Scholar
  66. 66.
    Lamping DL, Joseph L, Ryan B, Gilmore N. Psychological distress in persons affected with HIV in Montreal (French). Sante Ment Que 1992; 17: 73–95.Google Scholar
  67. 67.
    von Neumann J, Morgenstern O. Theory of games and economic behaviour. Princeton, NJ: Princeton University Press, 1944.Google Scholar
  68. 68.
    Torrance GW, Thomas WH, Sackett DL A utility maximization model for evaluation of health care programs. Health Service Res 1972; 7: 118.Google Scholar
  69. 69.
    Gange SJ, Jacobson LP, Kass N et al. Quality of life among seropositive patients on monotherapy and combination antiretroviral therapy. Qual Life Res, in press.Google Scholar
  70. 70.
    Lamping DL, Abrahamowicz M, Gilmore N, et al: A randomized, controlled trial to evaluate a psychosocial intervention to improve quality of life in HIV infection. In: Ninth International Conference on AIDS, Berlin, June 1993.Google Scholar
  71. 71.
    Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients. A concise QL-Index for use by physicians. J Chronic Dis 1981; 34: 585–597.Google Scholar
  72. 72.
    Arpinelli F, Visona G, de Carli G, Paparatti UDL, Recchia G. HIV positivity impact on quality of life in asymptomatic patients. DIA Quality of Life Symposium. Charleston, SC. 12–14 May, 1997.Google Scholar
  73. 73.
    Grant I, Atkinson JH, Hesselink JR et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency Virus (HIV) infections. Ann Intern Med 1987; 107: 828–836.Google Scholar
  74. 74.
    Ware JE, Koskinski M, Keller SD. The 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–233.Google Scholar
  75. 75.
    Berry SH, Bozzette SA, Hays RD, Stewart A, Kanouse DE. Measuring patient reported health status and experience in advanced HIV disease: HIV-PARSE Survey Instrument. Santa Monica, CA. RAND, 1991.Google Scholar
  76. 76.
    Powderly WG, Kinkelstein, DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection, N Engl J Med 1995; 332: 700–705.Google Scholar
  77. 77.
    Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebocontrolled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873–82.Google Scholar
  78. 78.
    Smereck G, Melchior L, Huba G, Andersen M. Social and Health Functioning in Substance Abusing Women with HIV. The Measurement Group, 1997.Google Scholar
  79. 79.
    Bozzette SA, Berry SH, Duan N, Kanouse D. Measuring Patient-centered Outcomes in the Pfizer-CCTG Trial of Azithromycin vs. Rifabutin vs. Both for the Prevention of HIV-associated Mycobacterium avium: Instruments, Methods, Application, and Results. RAND, 1996.Google Scholar
  80. 80.
    Brown V, Melchior L, Huba G. Level of Burden among Women with HIV. The Measurement Group. http://www.tmg-web.comGoogle Scholar
  81. 81.
    Hays RD, Shapiro MF: An overview of generic health related quality of life measures for HIV research. Qual Life Res 1992; 1: 91–98.Google Scholar
  82. 82.
    Cunningham WE, Hays RD, Williams KW, et al. Access to medical care and health-related quality of life for low income, symptomatic, HIV-infected individuals. Med Care 1995; 33: 739–754.Google Scholar
  83. 83.
    Ettl M, Hays RD, Cunningham W, Shapiro MF, Beck CK. Assessing health-related quality of life in disadvantaged and very ill populations. In Spilker B, ed., Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. New York: Lippincott-Raven Publishers, 1996: 595–604.Google Scholar
  84. 84.
    Hays RD, Cunningham WE, Ettl MK, Beck CK, Shapiro M. Health-related quality of life in HIV disease. Assessment 1995; 2: 363–380.Google Scholar
  85. 85.
    Hays RD, Cunningham WE, Shapiro MF. Derivation of Physical and Mental Health Composite Indices in the HIV Outcomes Study. Santa Monica, CA, 1996.Google Scholar
  86. 86.
    Cunningham WE, Hays RD, Ettl MK, et al. The prospective effect of access to medical care on health-related quality of life outcomes in patients with symptomatic HIV disease. Med Care In press.Google Scholar
  87. 87.
    Shapiro M, Bozzette S, Morton S, Frankel S, Berry S. HIV cost and service utilization study: studying health care issues in a national probability sample. In: Association for Health Services Research 13th Annual Meeting, Atlanta GA, June 1996.Google Scholar
  88. 88.
    Lubeck DP, Fries JF: changes in quality of life among persons with HIV infection. Qual Life Res 1992; 1(6): 359–366.Google Scholar
  89. 89.
    Cleary PD, Fowler FJ, Weissman J et al: health-related quality of life in persons with AIDS. Med Care. 1993, 31: 569–580.Google Scholar
  90. 90.
    Jette AM, Davies AR, Cleary PD et al: The functional status questionnaire: its reliability and validity when used in primary care. J Gen Intern Med 1986; 1: 143.Google Scholar
  91. 91.
    Lenderking WR, Testa MA, Katzenstein D, Hammer S. Measuring quality of life in HIV-infected asymptomatic patients: The modular approach. Qual Life Res, in press.Google Scholar
  92. 92.
    Testa MA, Lenderking WR, Fischer L, Revicki DA, Collier AC. Effects of combination therapy with saquinavir, zidovudine, and zalcitabine on quality of life. In: XI International Conference on AIDS, Vancouver.Google Scholar
  93. 93.
    Testa MA, Simonson DC. Measuring quality of life in hypertensive patients with diabetes. Postgrad Med J 1988; 64: 50–58.Google Scholar
  94. 94.
    Stewart AL, Ware JE, eds. Measuring Functioning and Well-being. The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.Google Scholar

Copyright information

© Chapman and Hall 1997

Authors and Affiliations

  • A. W. Wu
    • 1
  • R. D. Hays
    • 2
  • S. Kelly
    • 3
  • F. Malitz
    • 4
  • S. A. Bozzette
    • 5
  1. 1.Department of Medicine, School of MedicineThe Johns Hopkins UniversityBaltimoreUSA
  2. 2.Department of MedicineUniversity of California Los AngelesLos AngelesUSA
  3. 3.Social and Scientific Systems, IncRockvilleUSA
  4. 4.Department of Health Policy and Management, School of Hygiene and Public HealthThe Johns Hopkins UniversityBaltimioreUSA
  5. 5.University of California, San DiegoLa JollaUSA The leading health status instruments in human immunodeficiency virus (HIV) research are based on the pool of items developed as part of the Medical Outcomes Study (MOS). The measures include the SF-20, MOS-HIV, SF-36, SF-12, SF-56, SF-38 (Patient Reported Status and Experience Survey (PARSE)), SF-21 and HIV Cost and Service Utilization Study (HCSUS) questionnaires. The instrument length ranges from 12 to 56 items, covering two to 11 dimensions. Completion requires from 2 to 14 minutes. Subscales are scored on a 0–100 scale (a higher score indicates better health); physical and mental health or overall summary scores are available for most of the measures. Three of the instruments are available in multiple languages. The instruments have been administered to over 20,000 persons with HIV in descriptive studies and clinical trials and there is substantial evidence for their reliability, construct and predictive validity and responsiveness. In several studies the measures have shown important differences between treatments. Although existing measures do not assess all domains relevant to HIV disease, additional subscales are available from the MOS pool. Some of the subscales may be prone to floor and ceiling effects. However, summary scales that encompass all of the subscales reduce this issue. Selection among MOS measures should be dictated by specific questions, the balance of available time and resources, and practical concerns

Personalised recommendations